Clinical Trials Browser

Phase 1/2 × Solid Tumor, Adult × pazopanib × Clear all

NCT06895733 2025-03-26

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult